David Dodds

David Dodds has been working in the field of pharma, renewable/bio-based chemicals, and industrial biotech since 2002. David began by founding Dodds & Associates LLC, where they have provided executive level technical strategy, project management, and due diligence. In 2005, they began working as a senior advisor for Rondaxe Pharma. In 2012, they joined the Scientific Advisory Board of PureVision Technologies Inc., and in 2014 they became an Executive Officer of the Committee E62 Industrial Biotechnology at ASTM International. In 2016, they became an Expert at Lee Enterprises Consulting, Inc., and in 2017 they served as Interim CTO for Azitra, Inc. In 2019, they co-founded keydabra, and in 2020 they began working as an advisor for GALY, eventually taking on the role of Chief Technology Officer in 2022. David also serves on the Scientific Advisory Board of zuChem.

David Dodds completed their education history with a Ph.D. in Organic Chemistry from the University of Toronto under the supervision of Prof. Bryan Jones from 1979 to 1984. Afterwards, they completed a Post-doc in Molecular Biology from the University of Colorado Boulder under the supervision of Prof. Marv Caruthers from 1984 to 1986. Prior to that, they earned a M.Sc. in Biorganic Chemistry from the University of Toronto from 1977 to 1979. David started their academic career with a B.Sc. in Chem & Biochem from the University of Toronto - University of Trinity College from 1973 to 1977. David 's educational journey began at the University of Toronto Schools from 1968 to 1973.